# DESCRIPTION

## GOVERNMENT FUNDING

- acknowledge government support

## BACKGROUND

- introduce PIK3CA
- describe PI3K function

## SUMMARY

- introduce PIK3CA helical domain mutations
- describe p85β disassociation
- explain nuclear p85β-USP7-EZH1/2 axis
- describe canonical p110-PDK1-AKT pathway
- summarize therapeutic approach
- list EZH inhibitors
- list PI3K inhibitors
- describe cancer types

## DETAILED DESCRIPTION

- define terms used in the specification
- explain meaning of transitional terms
- explain meaning of indefinite articles
- define "about" and "comprising essentially of"
- explain significance of endpoints and ranges
- provide examples of disclosed values
- define "cancer"
- list examples of cancers
- define "responsiveness"
- explain meaning of "sample"
- define "normal cell"
- explain "contacting a cell"
- define "candidate compound"
- explain "severity" of cancer
- describe cancer stage
- describe tumor grade
- describe histologic grade
- describe nuclear grade
- describe metastasis
- define "symptom"
- define "sign"
- define "subject"
- explain "therapeutically effective amount"
- explain "promoting cancer regression"
- describe tumor growth inhibition
- describe prophylactic treatment
- define "treatment"
- explain prevention of disease
- explain inhibition of disease
- explain relief of disease
- define "pharmaceutical formulation"
- explain sterility of formulation
- introduce PIK3CA helical domain mutant cancer
- describe PI3K structure
- describe PIK3CA mutations
- describe p85β disassociation from p110α
- describe nuclear translocation of p85β
- describe recruitment of USP7 by p85β
- describe stabilization of EZH1 and EZH2
- describe enhancement of H3K27Me3
- describe direct binding of p110α to IRS1
- describe activation of PDK1-AKT signaling
- summarize two independent oncogenic pathways
- describe PIK3CA helical domain mutant cancer treatment
- introduce combination therapy
- describe administration of combination therapy
- define synergistic effect
- describe combination therapy with non-drug treatment
- describe combination therapy with radiation therapy
- describe formulation of combination therapy
- describe pharmaceutical compositions
- describe EZH inhibitors
- describe PI3K inhibitors
- describe p110α inhibitors
- describe pharmaceutical composition formulation
- describe unit dosage form
- describe dosage forms for topical administration
- define pharmaceutically acceptable
- define pharmaceutically acceptable excipient
- describe routes of administration
- describe parenteral administration
- describe oral administration
- describe transdermal administration
- describe transmucosal administration
- describe pH adjustment
- describe tonicity adjustment
- describe antibacterial agents
- describe antioxidants
- describe chelating agents
- describe buffers
- describe administration methods
- describe dose determination
- describe therapeutic index
- describe dosage adjustment
- describe factors affecting dosage
- describe long-acting pharmaceutical compositions
- describe pharmaceutical composition manufacturing
- describe formulation of pharmaceutical compositions
- describe pharmaceutical compositions
- list carriers for injectable use
- describe preparation of sterile injectable solutions
- describe preparation of sterile powders
- describe oral compositions
- list ingredients for oral compositions
- describe administration by inhalation
- describe transmucosal or transdermal administration
- describe controlled release formulations
- describe liposomal suspensions
- describe dosage unit forms
- describe dosages
- describe factors affecting dosage
- describe techniques for formulation and administration
- describe pharmaceutical preparations
- describe subjects to be treated
- describe PIK3CA helical domain mutant cancer
- describe mutations in p110α helical domain
- describe refractory or resistant cancer
- describe secondary cancer
- describe resistance to EZH inhibitors or PIK3CA inhibitors
- list exemplary cancers
- describe PIK3CA helical domain mutant cancer in breast cancer
- describe PIK3CA helical domain mutant cancer in colon cancer
- describe PIK3CA helical domain mutant cancer in lung cancer
- describe PIK3CA helical domain mutant cancer in pancreatic cancer
- describe PIK3CA helical domain mutant cancer in prostate cancer
- describe PIK3CA helical domain mutant cancer in skin cancer
- describe PIK3CA helical domain mutant cancer in ovarian cancer
- describe PIK3CA helical domain mutant cancer in breast cancer
- describe PIK3CA helical domain mutant cancer in other cancers
- describe PIK3CA helical domain mutant cancer in combination with other therapies
- describe PIK3CA helical domain mutant cancer in combination with EZH inhibitors
- describe PIK3CA helical domain mutant cancer in combination with PIK3CA inhibitors
- describe PIK3CA helical domain mutant cancer in combination with other therapeutic agents
- describe pharmaceutical compositions for PIK3CA helical domain mutant cancer
- describe administration of pharmaceutical compositions
- describe dosage regimens
- describe factors affecting dosage regimens
- describe techniques for formulation and administration
- describe pharmaceutical preparations for PIK3CA helical domain mutant cancer
- describe subjects to be treated with PIK3CA helical domain mutant cancer
- define breast cancer
- describe types of breast cancer
- describe staging of breast cancer
- describe grading of breast cancer
- describe tumor characteristics
- describe treatment of PIK3CA helical domain mutant cancer
- describe reduction in tumor size
- describe reduction in tumor volume
- describe decrease in number of tumors
- describe decrease in number of metastatic lesions
- describe increase in average survival time
- describe decrease in mortality rate
- describe decrease in tumor growth rate
- describe decrease in tumor regrowth
- describe reduction in rate of cellular proliferation
- describe reduction in proportion of proliferating cells
- describe decrease in size of area of cellular proliferation
- describe decrease in number of cells with abnormal morphology
- describe cell death
- describe non-cytotoxicity to normal cells
- describe detection of mutant PIK3CA helical domain
- describe determination of suitability for treatment
- describe assessing mutant PIK3CA helical domain
- describe transformative method of assaying
- describe providing intermediate result
- describe performing steps by medical practitioner
- describe assessing proportion of cells with mutant PIK3CA helical domain
- describe determining presence of PIK3CA helical domain RNA
- describe predicting therapeutic effectiveness
- describe providing test tissue sample
- describe assaying test tissue sample
- describe comparing proportion with threshold value
- describe predicting effectiveness of treatment
- describe exceeding threshold proportion
- describe not exceeding threshold proportion
- describe further illustration by examples
- describe contents of figures
- describe contents of references
- describe patents and published patent applications
- describe express incorporation by reference
- describe breast cancer treatment
- describe PIK3CA helical domain mutant cancer treatment
- describe inhibitor of nuclear translocation of p85β
- describe EZH inhibitor
- describe PI3K inhibitor
- describe combination therapy
- describe therapeutic effectiveness

### Example 1

- show p85 β disassociation from p110α and translocation into nucleus in cancer cells

### Materials & Methods

- describe tissue culture and transfection
- specify cell lines and media used
- outline transfection procedure
- describe DNA constructs and mutagenesis
- specify plasmids used
- outline site-directed mutagenesis kit
- describe CRISPR/CAS9 genome editing
- specify guiding RNA pairs designed
- outline lentiCRISPRv2 vector cloning
- describe puromycin selection
- outline genomic PCR and Western blot validation
- describe siRNA knockdown
- specify siRNAs targeting human PIK3R2/p85β
- outline RNA extraction and quantitative real-time PCR
- describe cell growth assays
- outline immunofluorescence staining
- describe co-immunoprecipitation and Western blotting
- outline nuclear/cytoplasmic fractionation
- describe xenografts
- outline drug treatment

### Results

- demonstrate p110α E545K mutant protein reduces binding to p85β
- validate results with reciprocal immunoprecipitation
- show more PI3K complex-free p85β in E545K-only cells
- validate results with gel-filtration analyses
- determine which p110α mutations affect binding to p85β
- show p110α E542K and Q546K mutant proteins disrupt interactions with p85β
- show p110α H1047R mutant protein has no impact on p85β binding
- assess p85β-p110 complex formation in six cell lines
- show weaker interactions between p85β and p110α in PIK3CA E545K mutation cell lines
- show similar interactions between p85β and p110β or p85α and p110α
- suggest p85β dissociates from mutant p110α in cancer cells
- align protein sequences of p85α and p85β
- construct chimeric p85 proteins to swap N-terminus regions
- show N-terminal p85α-C-terminal p85β chimeric proteins bind similarly to p110α WT and E545K mutant proteins
- show N-terminal p85β-C-terminal p85α chimeric protein binds less to p110α E545K mutant protein
- suggest N-terminal sequences of p85β cause its disassociation from p110α helical domain mutant proteins
- analyze TCGA datasets to assess p85β expression levels and clinical outcomes
- show high expression of PIK3R2 is associated with poor five-year survival in helical domain mutation group
- knock out p85β in isogenic DLD1 cell lines to investigate its function
- show p85β promotes tumorigenesis in tumors with a PIK3CA helical domain mutation
- introduce p85β nuclear translocation
- identify NLS in p85β
- test NLS mutation effect on nuclear translocation
- show WT p85β rescues cell growth defects
- generate p85β NLS mutant knockin cells
- analyze p85β NLS mutant cell lines
- show nuclear p85β promotes cancer cell growth
- perform expression profiling
- examine histone modifications
- show nuclear p85β regulates H3K27me3
- examine EZH1 and EZH2 protein levels
- show nuclear p85β regulates EZH1 and EZH2 stability
- analyze EZH1 and EZH2 protein stability
- examine mRNA levels of EZH1 and EZH2
- show nuclear p85β recruits USP7 to EZH1 and EZH2
- examine USP7 interaction with EZH1 and EZH2
- show EZH1 and EZH2 ubiquitination levels
- test combination of EZH inhibitor and p110α inhibitor
- show tumor regression with drug combination
- test drug combination on different PIK3CA mutations
- analyze pAKT and H3K27me3 levels
- discuss nuclear p85β-USP7-EZH1/2 axis
- discuss canonical p110-PDK1-AKT pathway
- discuss therapeutic approach for PIK3CA helical domain mutant cancers
- discuss nuclear translocation and function of p85β
- discuss oncogenic role of nuclear p85β
- discuss nuclear p85β-stabilized EZHs and p110α
- discuss cancer treatment approach

### Example 2

- demonstrate combination therapy
- scope of appended claims

